Daymark Wealth Partners LLC Purchases 664 Shares of Becton, Dickinson and Company $BDX

Daymark Wealth Partners LLC increased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 38.6% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,385 shares of the medical instruments supplier’s stock after acquiring an additional 664 shares during the quarter. Daymark Wealth Partners LLC’s holdings in Becton, Dickinson and Company were worth $411,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of BDX. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $26,000. Cornerstone Planning Group LLC increased its stake in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock valued at $29,000 after purchasing an additional 99 shares in the last quarter. Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $31,000. Bank of Jackson Hole Trust increased its stake in Becton, Dickinson and Company by 85.6% during the 2nd quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock valued at $35,000 after purchasing an additional 95 shares in the last quarter. Finally, WPG Advisers LLC acquired a new position in Becton, Dickinson and Company during the 1st quarter valued at approximately $36,000. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total transaction of $171,937.50. Following the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders have sold 1,895 shares of company stock worth $358,995 over the last quarter. Corporate insiders own 0.36% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have issued reports on BDX shares. Morgan Stanley upped their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Piper Sandler reaffirmed a “neutral” rating and issued a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Argus upped their price objective on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Finally, Wall Street Zen raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Three research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX opened at $179.07 on Friday. The company’s fifty day moving average price is $188.79 and its 200 day moving average price is $183.36. Becton, Dickinson and Company has a 1 year low of $163.33 and a 1 year high of $251.99. The company has a market capitalization of $51.33 billion, a PE ratio of 32.21, a price-to-earnings-growth ratio of 1.42 and a beta of 0.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 1.10.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.32 billion for the quarter. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.